LZWL02003

LZWL02003 is a synthetic small molecule derivative of N-salicyloyl tryptamine, created by combining melatonin and salicylic acid. It demonstrates significant **neuroprotective**, **anti-apoptotic**, **antioxidative**, and **anti-neuroinflammatory** activities in both in vitro and in vivo models. LZWL02003 has shown efficacy in experimental models of **cerebral ischemia/reperfusion (I/R) injury** and **Parkinson’s disease (PD)**, where it prevents neuronal apoptosis (by modulating Bcl-2 and Bax expression), reduces oxidative stress (reduces malondialdehyde and reactive oxygen species, increases superoxide dismutase), restores mitochondrial function, and suppresses neuroinflammation (decreases IL-1β, TNF-α, IL-6; increases IL-4, IL-10). The compound inhibits activation and nuclear translocation of the NF-κB pathway and reduces glial cell activation (astrocytes and microglia). It also displays good blood–brain barrier permeability and low toxicity in preclinical studies. LZWL02003 is regarded as a potential candidate for **ischemic stroke**, **Parkinson’s disease**, and theoretically other neurodegenerative diseases[1][3][4][5][7].

Other names

N-salicyloyl tryptamine derivative